ImmunityBio, Inc.

Quick facts

Marketed products

• Anktiva · Other
• Lovaza · Other

Phase 3 pipeline

• NAI + Nivolumab + Ipilimumab · Oncology
  This triple combination enhances anti-tumor immunity by activating natural killer cells (NAI), blocking PD-1 checkpoint inhibition (Nivolumab), and blocking CTLA-4 checkpoint inhibition (Ipilimumab).
• NAI + Pembrolizumab · Oncology
  NAI is a cGAS-STING agonist that activates innate immune signaling, combined with pembrolizumab, a PD-1 checkpoint inhibitor, to enhance anti-tumor immune responses.

Phase 2 pipeline

• Aldoxorubicin HCl · Oncology
  Aldoxorubicin HCl is a prodrug that selectively releases doxorubicin in acidic environments, such as tumor cells, to exert its cytotoxic effects.
• ALT-803 · Oncology
  ALT-803 is an IL-15 superagonist that stimulates the expansion of natural killer cells and CD8+ T cells.
• CD19 t-haNK- IV Administration · Oncology
  CD19 t-haNK- is a type of immunotherapy that targets and kills cancer cells by harnessing the power of a patient's own immune system.
• ETBX-071
• M-CENK · Oncology
  M-CENK is a cancer immunotherapy that targets the CD47/SIRPα axis.
• N-803 and BCG
• N-803 and Gemcitabine
• rMBCG

Phase 1 pipeline

• CD19 t-haNK
• CD19t-haNK suspension
• IBRX-042

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ImmunityBio, Inc. portfolio CI brief
• ImmunityBio, Inc. pipeline updates RSS